Zachary J Tabb1, Blandina T Mmbaga2,3, Monica Gandhi4, Alexander Louie4, Karen Kuncze4, Hideaki Okochi4, Aisa M Shayo3, Elizabeth L Turner5,6, Coleen K Cunningham5,7, Dorothy E Dow2,5,7. 1. The Alpert Medical School of Brown University, Providence, Rhode Island, USA. 2. Kilimanjaro Christian Medical Centre-Duke Collaboration, Moshi. 3. Department of Pediatrics, Kilimanjaro Christian Medical Centre, Moshi, Tanzania. 4. Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, California. 5. Duke Global Health Institute. 6. Department of Biostatistics and Bioinformatics, Duke University, Durham. 7. Division of Pediatric Infectious Diseases, Duke University Medical Center, Durham, North Carolina, USA.
Abstract
OBJECTIVE: We assessed the relationship of self-reported adherence versus antiretroviral therapy (ART) concentrations in hair with virologic outcomes among young people living with HIV. DESIGN: This was a cross-sectional study that enrolled young people living with HIV age 11-24 years, who attended a youth HIV clinic in Moshi, Tanzania. METHODS: ART adherence was assessed by self-report, drug concentration in hair samples, and plasma HIV-1 RNA measurements. Those with virologic failure, defined as plasma HIV-1 RNA more than 400 copies/ml, had genotypic resistance assessed. Receiver operating characteristic curves were used to evaluate ART-concentration threshold cutoffs for virologic suppression, after excluding those with known high-level resistance mutations. RESULTS: Among 280 young people enrolled, 227 were included in the final analysis. Seventy-two (32%) self-reported inadequate adherence and 91 (40%) had virologic failure. Hair ART-concentration (P < 0.001), but not self-reported adherence (P = 0.53), was associated with virologic outcome. Sixty-seven (74%) of those with virologic failure had resistance testing performed, of whom 60% had high-level resistance. Receiver operating characteristic curves demonstrated moderate or high classification performance for association with virologic suppression with specific hair ART-concentration cutoffs for lopinavir (1.8 ng/mg), efavirenz (1.04 ng/mg), and nevirapine (33.2 ng/mg). CONCLUSION: Hair ART-concentrations were significantly associated with virologic outcomes among young people living with HIV. ART-concentration thresholds associated with virologic suppression are proposed. Hair analysis may provide a noninvasive, cost-effective adherence assessment tool in settings with limited second and third-line treatment options.
OBJECTIVE: We assessed the relationship of self-reported adherence versus antiretroviral therapy (ART) concentrations in hair with virologic outcomes among young people living with HIV. DESIGN: This was a cross-sectional study that enrolled young people living with HIV age 11-24 years, who attended a youth HIV clinic in Moshi, Tanzania. METHODS:ART adherence was assessed by self-report, drug concentration in hair samples, and plasma HIV-1 RNA measurements. Those with virologic failure, defined as plasma HIV-1 RNA more than 400 copies/ml, had genotypic resistance assessed. Receiver operating characteristic curves were used to evaluate ART-concentration threshold cutoffs for virologic suppression, after excluding those with known high-level resistance mutations. RESULTS: Among 280 young people enrolled, 227 were included in the final analysis. Seventy-two (32%) self-reported inadequate adherence and 91 (40%) had virologic failure. Hair ART-concentration (P < 0.001), but not self-reported adherence (P = 0.53), was associated with virologic outcome. Sixty-seven (74%) of those with virologic failure had resistance testing performed, of whom 60% had high-level resistance. Receiver operating characteristic curves demonstrated moderate or high classification performance for association with virologic suppression with specific hair ART-concentration cutoffs for lopinavir (1.8 ng/mg), efavirenz (1.04 ng/mg), and nevirapine (33.2 ng/mg). CONCLUSION: Hair ART-concentrations were significantly associated with virologic outcomes among young people living with HIV. ART-concentration thresholds associated with virologic suppression are proposed. Hair analysis may provide a noninvasive, cost-effective adherence assessment tool in settings with limited second and third-line treatment options.
Authors: Susan D Emmett; Coleen K Cunningham; Blandina T Mmbaga; Grace D Kinabo; Werner Schimana; Mark E Swai; John A Bartlett; John A Crump; Elizabeth A Reddy Journal: J Acquir Immune Defic Syndr Date: 2010-08 Impact factor: 3.731
Authors: Alexandra D Müller; Heather B Jaspan; Landon Myer; Ashley Lewis Hunter; Guy Harling; Linda-Gail Bekker; Catherine Orrell Journal: AIDS Behav Date: 2011-02
Authors: Sulachni Chandwani; Linda J Koenig; Anne M Sill; Susan Abramowitz; Latoya C Conner; Lawrence D'Angelo Journal: J Adolesc Health Date: 2012-03-03 Impact factor: 5.012
Authors: Sanjiv M Baxi; Ruth M Greenblatt; Peter Bacchetti; Chengshi Jin; Audrey L French; Marla J Keller; Michael H Augenbraun; Stephen J Gange; Chenglong Liu; Wendy J Mack; Monica Gandhi Journal: PLoS One Date: 2015-06-08 Impact factor: 3.240
Authors: Daniel Na Ankrah; Ellen S Koster; Aukje K Mantel-Teeuwisse; Daniel K Arhinful; Irene A Agyepong; Margaret Lartey Journal: Patient Prefer Adherence Date: 2016-03-15 Impact factor: 2.711
Authors: A T Makadzange; M Higgins-Biddle; B Chimukangara; R Birri; M Gordon; T Mahlanza; G McHugh; J H van Dijk; M Bwakura-Dangarembizi; T Ndung'u; C Masimirembwa; B Phelps; A Amzel; B O Ojikutu; B D Walker; C E Ndhlovu Journal: PLoS One Date: 2015-12-14 Impact factor: 3.240
Authors: Matthew A Spinelli; Jessica E Haberer; Peter R Chai; Jose Castillo-Mancilla; Peter L Anderson; Monica Gandhi Journal: Curr HIV/AIDS Rep Date: 2020-08 Impact factor: 5.071
Authors: Jacinta N Nwogu; Chinedum P Babalola; Samuel O Ngene; Babafemi O Taiwo; Baiba Berzins; Monica Gandhi Journal: AIDS Res Hum Retroviruses Date: 2019-05-29 Impact factor: 2.205
Authors: Pamela M Murnane; Monica Gandhi; Peter Bacchetti; Monica Getahun; Sarah A Gutin; Hideaki Okochi; Irene Maeri; Patrick Eyul; Daniel Omoding; Jaffer Okiring; Regina Tallerico; Alexander Louie; Adam Akullian; Moses R Kamya; Elizabeth A Bukusi; Edwin D Charlebois; Carol S Camlin Journal: AIDS Date: 2022-03-04 Impact factor: 4.632
Authors: Mira Wang; Joshua D Miller; Shalean M Collins; Marianne V Santoso; Pauline Wekesa; Hideaki Okochi; Maricianah Onono; Sheri Weiser; Monica Gandhi; Sera L Young Journal: AIDS Behav Date: 2020-10
Authors: Babafemi O Taiwo; Kehinde M Kuti; Lisa M Kuhns; Olayinka Omigbodun; Olutosin Awolude; Adedotun Adetunji; Baiba Berzins; Patrick Janulis; Amy K Johnson; Ogochukwu Okonkwor; Bibilola D Oladeji; Abigail Muldoon; Olubusuyi M Adewumi; Paul Amoo; Hannah Atunde; Bill Kapogiannis; Robert Garofalo Journal: J Acquir Immune Defic Syndr Date: 2021-08-01 Impact factor: 3.771
Authors: Tanakorn Apornpong; Beatriz Grinsztejn; Michael Hughes; Justin Ritz; Stephen J Kerr; Courtney V Fletcher; Kiat Ruxrungtham; Catherine Godfrey; Robert Gross; Evelyn Hogg; Carole L Wallis; Sharlaa Badal-Faesen; Mina C Hosseinipour; Rosie Mngqbisa; Breno R Santos; Sarita Shah; Laura J Hovind; Sajeeda Mawlana; Marije Van Schalkwyk; Nuntisa Chotirosniramit; Cecilia Kanyama; Nagalingeswaran Kumarasamy; Robert Salata; Ann C Collier; Monica Gandhi Journal: AIDS Date: 2021-07-15 Impact factor: 4.632